Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Yes or no to local therapy for oligometastatic prostate cancer?

Nature Reviews Urology volume 15, pages 399–400 (2018)Cite this article

Subjects

Metastatic prostate cancer has traditionally been treated with systemic therapy alone, but the issue of oligometastatic disease raises the question of whether local therapy — radical prostatectomy or prostate radiotherapy — should be performed. A number of phase III trials should improve our understanding of metastatic disease and lead to better care of our patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Rationale for treating the primary tumour.

References

  1. Tosoian, J. J. et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol. 14, 15–25 (2017).

    Article  PubMed  CAS  Google Scholar 

  2. Dall’Era, M. A. et al. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. Cancer 124, 1921–1928 (2018).

    Article  PubMed  CAS  Google Scholar 

  3. Lee, S. U. & Cho, K. H. Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy &rogen deprivation therapy and their combination. Radiat. Oncol. J. 35, 189–197 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378–382 (2011).

    Article  PubMed  CAS  Google Scholar 

  5. deSouza, N. M. et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur. J. Cancer. 91, 153–163 (2018).

    Article  PubMed  Google Scholar 

  6. Sooriakumaran, P. et al. Multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur. Urol. 69, 788–794 (2016).

    Article  PubMed  Google Scholar 

  7. Heidenreich, A., Pfister, D. & Porres, D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J. Urol. 193, 832–838 (2015).

    Article  PubMed  Google Scholar 

  8. Stewart, S. B. et al. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J. Urol. 187, 103–108 (2012).

    Article  PubMed  Google Scholar 

  9. Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446–453 (2018).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery and Duke Cancer Institute, Duke University, Durham, NC, USA

    Judd W. Moul

Authors
  1. Judd W. Moul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Judd W. Moul.

Ethics declarations

Competing interests

The author declares research support from and has acted as an adviser or speaker for Astellas, Bayer, Dendreon, Janssen, Ferring, Pfizer, and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moul, J.W. Yes or no to local therapy for oligometastatic prostate cancer?. Nat Rev Urol 15, 399–400 (2018). https://doi.org/10.1038/s41585-018-0028-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0028-7

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer